Docetaxel in Castration-Resistant Prostate Cancer: A Single-Centre Experience

Detti BeatriceDepartment of Radiation-Oncology, University of Florence, Florence, Italy,

Franceschini DavideDepartment of Radiation-Oncology, University of Florence, Florence, Italy,Correspondence[email protected]

Saieva CalogeroMolecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Center (ISPO), Florence, Italy

Di Brina LuciaDepartment of Radiation-Oncology, University of Florence, Florence, Italy,

Baki MohammedDepartment of Radiation-Oncology, University of Florence, Florence, Italy,

Meattini IcroDepartment of Radiation-Oncology, University of Florence, Florence, Italy,

Di Cataldo VanessaDepartment of Radiation-Oncology, University of Florence, Florence, Italy,

Monteleone Pasquetti EleonoraDepartment of Radiation-Oncology, University of Florence, Florence, Italy,

Furfaro IlariaDepartment of Radiation-Oncology, University of Florence, Florence, Italy,

Mancuso AnnaDepartment of Radiation-Oncology, University of Florence, Florence, Italy,

Simontacchi GabrieleDepartment of Radiation-Oncology, University of Florence, Florence, Italy,

Livi LorenzoDepartment of Radiation-Oncology, University of Florence, Florence, Italy,

show all

Abstract

We present a single-institution experience reporting the efficacy and safety of docetaxel, administered as first-line chemotherapy, in castration-resistant prostate cancer (CRPC), focusing on patients and treatment parameters.

From November 2004 to January 2012, 51 patients received chemotherapy with docetaxel. With a mean follow-up time (from the beginning of CHT) of 1.6 years (range 0.1–5.1 years), 35 patients (68.6%) died for prostate cancer and 48 patients (94.1%) showed progression of the disease.

Five factors influenced overall survival: nodal status at diagnosis, neoadjuvant hormonal therapy, number of cycles of docetaxel administered, schedule of docetaxel and ECOG performance status before starting chemotherapy.

Keywords: :

View correction statement:

Docetaxel in Castration-Resistant Prostate Cancer: A Single-Centre Experience

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Docetaxel in Castration-Resistant Prostate Cancer: A Single-Centre Experience

Information for

Open access

Opportunities

Help and information

Docetaxel in Castration-Resistant Prostate Cancer: A Single-Centre Experience

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature